BioCentury
ARTICLE | Clinical News

HQK-1001: Phase II started

May 2, 2011 7:00 AM UTC

HemaQuest began an open-label, dose-escalation, international Phase II trial to evaluate 30, 40 and 50 mg/kg oral HQK-1001 daily for 26 weeks in about 50 patients. The compound has Orphan Drug designa...